So, the big question is: Should employers see these medications as a smart investment in employee health or are they an ongoing financial risk thats hard to sustain
Rolfo C, Giovannetti E, Martinez P, McCue S, Naing A
doi: 10.1016/s0168-1605(00)00456-6 226 KullisaarTZilmerMMikelsaarMVihalemmTAnnukHKairaneCet al
(13), the subcutaneous implantation of E2 silicone capsules demonstrated that supplementation with low concentrations of E2 (30 mg/mL) significantly diminished the apnea reflex induced by CIH in OVX rats, as well as the afferent response to chemical stimuli and the pulmonary inflammatory response
However, during prolonged stimulation, -arrestin-2 exerts a desensitizing influence, promoting receptor down-regulation and lysosomal targeting, thereby reducing long-term responsiveness